advertisement
Abstract #99122 Published in IGR 22-4
Noninferiority Study Comparing Latanoprost 0.005% Without Versus With Benzalkonium Chloride in Open-Angle Glaucoma or Ocular Hypertension
Wirta D; Malhotra R; Peace J; Shen Lee B; Mitchell B; Sall K; McMenemy MEye Contact Lens 2022; 48: 149-154
OBJECTIVES: To evaluate the noninferiority of intraocular pressure (IOP)-lowering latanoprost without benzalkonium chloride (BAK) versus latanoprost with BAK (for treatment of open-angle glaucoma or ocular hypertension). METHODS: Overall, 578 patients were randomized 1:1 to latanoprost without BAK or latanoprost with BAK once daily in the affected eye(s) for 12 weeks. The primary efficacy endpoint was IOP, measured on days 0, 7, 28, 56, and 84 (8 am, 10 am, and 4 pm). Noninferiority was established if the following criteria were met: 95% confidence interval (CI) of the mean difference between treatments included 0 mm Hg for all time points (N1), 95% CI upper limit less than 1.5 mm Hg (N2), and less than 1 mm Hg for≥7 of 12 time points (N3). Primary efficacy analysis was performed on the intent-to-treat population. Safety measurements included ocular and systemic adverse event (AE). RESULTS: The 95% CI included 0 mm Hg for 7/12 time points (N1), 95% CI upper limit was less than 1.5 mm Hg for 12/12 time points (N2), and less than 1.0 mm Hg for 4/7 time points (N3). AEs were mild and similarly distributed between groups. CONCLUSIONS: Latanoprost without BAK did not meet two of three criteria for noninferiority and showed a similar safety profile relative to latanoprost with BAK.
Eye Research Foundation (D.W.), Newport Beach, CA; Ophthalmology Associates (R.M.), St. Louis, MO; Peace Eyecare (J.P.), Inglewood, CA; Vision Optique (B.S.L.), Houston, TX; Sun Pharmaceutical Industries, Inc., (B.M.) Princeton, NJ; Sall Research Medical Center, Inc., (K.S.) Artesia, CA; and Lone Star Eye Care, P.A (M.M.), Sugar Land, TX.
Full article